A new trading day began On Friday, with Regenxbio Inc (NASDAQ: RGNX) stock price down -3.76% from the previous day of trading, before settling in for the closing price of $8.51. RGNX’s price has ranged from $5.03 to $15.02 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -12.18% over the last five years. Meanwhile, its annual earnings per share averaged 93.62%. With a float of $45.66 million, this company’s outstanding shares have now reached $50.12 million.
The firm has a total of 353 workers. Let’s measure their productivity. In terms of profitability, gross margin is 76.54%, operating margin of -100.41%, and the pretax margin is -100.62%.
Regenxbio Inc (RGNX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Regenxbio Inc is 9.38%, while institutional ownership is 85.11%. The most recent insider transaction that took place on May 12 ’25, was worth 163,046. In this transaction Director of this company sold 20,602 shares at a rate of $7.91, taking the stock ownership to the 475,103 shares. Before that another transaction happened on May 12 ’25, when Company’s Director proposed sale 20,602 for $7.52, making the entire transaction worth $154,927.
Regenxbio Inc (RGNX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 93.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.89% during the next five years compared to -12.18% drop over the previous five years of trading.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Here are Regenxbio Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.14, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -1.52 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Analysing the last 5-days average volume posted by the [Regenxbio Inc, RGNX], we can find that recorded value of 0.71 million was lower than the volume posted last year of 0.99 million. As of the previous 9 days, the stock’s Stochastic %D was 31.82%.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 52.89%, which indicates a significant increase from 12.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.50 in the past 14 days, which was lower than the 0.70 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.92, while its 200-day Moving Average is $8.39. Now, the first resistance to watch is $8.41. This is followed by the second major resistance level at $8.62. The third major resistance level sits at $8.81. If the price goes on to break the first support level at $8.00, it is likely to go to the next support level at $7.81. Should the price break the second support level, the third support level stands at $7.60.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
With a market capitalization of 412.68 million, the company has a total of 50,160K Shares Outstanding. Currently, annual sales are 83,330 K while annual income is -227,100 K. The company’s previous quarter sales were 89,010 K while its latest quarter income was 6,080 K.
